Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sisunatovir for RSV in HCT Recipients
NCT04267822Phase 2Withdrawn
- Sponsor
- Pfizer
- Start
- Jun 2020
- Primary completion
- Jun 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of sisunatovir in respiratory syncytial virus infection (RSV), sponsored by Pfizer. Planned start Jun 2020; status: withdrawn.
02
Drugs
sisunatovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04267822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04267822.